SCHEMBL925082

SCHEMBL925082

CC(=O)Nc1nc(C)c(-c2ccc(NC(=O)OC(C)(C)C)cn2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 9/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
PI4KB Q9UBF8 2/20 0.50
POLB P06746 1/20 0.50
PIK3CA P42336 2/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 2/20 0.48
GAA P10253 2/20 0.48
MAPT P10636 2/20 0.48
HPGD P15428 1/20 0.48
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
GFER P55789 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL926639 0.77 PIK3CG (0.62) PIK3CGMEN1KMT2API4KBPOLB
SCHEMBL4207312 0.75 PIK3CG (0.57) PIK3CGMEN1KMT2API4KBPOLB
SCHEMBL924849 0.74 PIK3CD (0.61) PIK3CGMEN1KMT2APOLBPIK3CA
SCHEMBL4213933 0.74 PIK3CG (0.70) PIK3CGMEN1KMT2API4KBPOLB
SCHEMBL4214047 0.74 PIK3CG (0.59) PIK3CGMEN1KMT2API4KBPOLB
SCHEMBL926179 0.74 LMNA (0.57) PIK3CGMEN1KMT2APIK3CAALDH1A1
SCHEMBL9237307 0.73 CYP17A1 (0.48)
SCHEMBL26073587 0.72 CA12 (0.40)
SCHEMBL376258 0.71 NAMPT (0.56) NPSR1
SCHEMBL30208803 0.71 NAMPT (0.56) NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868188-B2 5-heteroaryl thiazoles and their use as PI3K inhibitors ASTRAZENECA AB (SE) 2011-01-11 US disclosed
EP-1841763-B1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS ASTRAZENECA AB (SE) 2010-06-30 EP disclosed
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors ASTRAZENECA AB (SE) 2008-06-05 US disclosed
EP-1841763-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS AstraZeneca AB (SE) 2007-10-10 EP disclosed
WO-2006051270-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS ASTRAZENECA AB (SE) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors MTOR, PIK3R5, PIK3CA PIK3CG 16/4885MEN1 1222/4885KMT2A 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.